GEMPHARMATECH LLC
- SAN DIEGO, CA 92121-1209
- gempharmatech.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $423.5K
- Awards on record
- 6
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
GEMPHARMATECH LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About GEMPHARMATECH LLC
- Headquarters
- SAN DIEGO, CA 92121-1209
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIH42SCKKGRTU3
- CAGE98AV0
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $423.5K
- Awards on record
- 6
- Top funding agencies
- National Institutes of Health · Department of Veterans Affairs
Awards
75N98026P01587
Recompete 6–12 mo: Potential end Sep 10, 2027 (9 months away)NCATS: SERVICE: EVALUATION OF A LEAD NNMT INHIBITOR IN HUMANIZED MOUSE MODELS OF CHRONIC KIDNEY DISEASE: SEVERABLE
Department of Health and Human Services · National Institutes of Health
- Obligated
- $89K
- Period of performance
- Sep 11, 2026 – Sep 10, 2027
75N95025P00413
Completed: Period of performance ended Sep 23, 2026SAFETY EVALUATION OF YC1 IN HSULT1A1 AND MSULT1A1 MICE.
Department of Health and Human Services · National Institutes of Health
- Obligated
- $58.9K
- Period of performance
- Sep 24, 2025 – Sep 23, 2026
75N95023P00824
Completed: Period of performance ended Sep 20, 2025DEVELOPING HUMANIZED MOUSE MODELS FOR NNMT AND SULT1A1
Department of Health and Human Services · National Institutes of Health
- Obligated
- $249.2K
- Period of performance
- Sep 22, 2023 – Sep 20, 2025
36C25224C0035
Completed: Period of performance ended Sep 14, 2025SAKSENA HYTEROZYGOTE GENERATION OF PGP/MDR1A FLOXED LIVE MICE GEMPHARMATECH LLC
Department of Veterans Affairs
- Obligated
- $12.9K
- Period of performance
- Sep 15, 2024 – Sep 14, 2025
75N95D24P00092
Completed: Period of performance ended Nov 19, 2024LIVE ANIMAL PRODUCTION- KREMEN1-FLOX MICE
Department of Health and Human Services · National Institutes of Health
- Obligated
- $13.5K
- Period of performance
- Aug 20, 2024 – Nov 19, 2024
75N94022P00404
Completed: Period of performance ended Jan 15, 2023NICHD - CONDITIONAL KNOCK-OUT MOUSE LINE
Department of Health and Human Services · National Institutes of Health
- Obligated
- $11.9K
- Period of performance
- May 31, 2022 – Jan 15, 2023
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N98026P01587 NCATS: SERVICE: EVALUATION OF A LEAD NNMT INHIBITOR IN HUMANIZED MOUSE MODELS OF CHRONIC KIDNEY DISEASE: SEVERABLE | Department of Health and Human Services · National Institutes of Health | 541714 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $89K | Sep 11, 2026 – Sep 10, 2027 | Recompete 6–12 mo: Potential end Sep 10, 2027 (9 months away)AI brief for award 75N98026P01587Bid team for the recompete of award 75N98026P01587 |
75N95025P00413 SAFETY EVALUATION OF YC1 IN HSULT1A1 AND MSULT1A1 MICE. | Department of Health and Human Services · National Institutes of Health | 541380 · Q301REFERENCE LABORATORY TESTING | $58.9K | Sep 24, 2025 – Sep 23, 2026 | Completed: Period of performance ended Sep 23, 2026 |
75N95023P00824 DEVELOPING HUMANIZED MOUSE MODELS FOR NNMT AND SULT1A1 | Department of Health and Human Services · National Institutes of Health | 541380 · Q301REFERENCE LABORATORY TESTING | $249.2K | Sep 22, 2023 – Sep 20, 2025 | Completed: Period of performance ended Sep 20, 2025 |
36C25224C0035 SAKSENA HYTEROZYGOTE GENERATION OF PGP/MDR1A FLOXED LIVE MICE GEMPHARMATECH LLC | Department of Veterans Affairs | 541714 · AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $12.9K | Sep 15, 2024 – Sep 14, 2025 | Completed: Period of performance ended Sep 14, 2025 |
75N95D24P00092 LIVE ANIMAL PRODUCTION- KREMEN1-FLOX MICE | Department of Health and Human Services · National Institutes of Health | 112990 · 8820LIVE ANIMALS, NOT RAISED FOR FOOD | $13.5K | Aug 20, 2024 – Nov 19, 2024 | Completed: Period of performance ended Nov 19, 2024 |
75N94022P00404 NICHD - CONDITIONAL KNOCK-OUT MOUSE LINE | Department of Health and Human Services · National Institutes of Health | 112990 · 8820LIVE ANIMALS, NOT RAISED FOR FOOD | $11.9K | May 31, 2022 – Jan 15, 2023 | Completed: Period of performance ended Jan 15, 2023 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
No SBIR/STTR awards on record
Source: SBIR.gov award records (opens in a new tab) · sync date not recorded
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with GEMPHARMATECH LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
